| Identification | Back Directory | [Name]
N-[3-[(benzoylcarbamothioylamino)carbamoyl]-4-(3,4-dimethoxyphenyl)-5-methylthiophen-2-yl]benzamide | [CAS]
713112-69-7 | [Synonyms]
SIC-19
N-[3-[(benzoylcarbamothioylamino)carbamoyl]-4-(3,4-dimethoxyphenyl)-5-methylthiophen-2-yl]benzamide
3-Thiophenecarboxylic acid, 2-(benzoylamino)-4-(3,4-dimethoxyphenyl)-5-methyl-, 2-[(benzoylamino)thioxomethyl]hydrazide | [Molecular Formula]
C29H26N4O5S2 | [MOL File]
713112-69-7.mol | [Molecular Weight]
574.67 |
| Hazard Information | Back Directory | [Uses]
SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib (HY-10162)), as well as in ovarian cancer organoids and xenograft models[1]. | [IC 50]
SIK2 | [References]
[1] Wang F, et al. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resist Updat. 2024 May;74:101077. DOI:10.1016/j.drup.2024.101077 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
|